Showing 2081-2090 of 2657 results for "".
- Researchers Found a Way to Reactivate Dormant Cells in the Retinahttps://modernod.com/news/researchers-found-a-way-to-reactivate-dormant-cells-in-the-retina/2481610/There's new hope for potentially restoring vision in patients suffering from degenerative retinal disease, thanks to work by researchers at Université de Montréal (UdeM). Published this week in Proceedings of the National Academy of Sciences, the research was
- FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)https://modernod.com/news/fda-accepts-application-for-genentechs-vabysmo-for-the-treatment-of-retinal-vein-occlusion-rvo/2481608/Genentech announced that the FDA has accepted the company’s supplemental biologics license application (sBLA) for Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). The sBLA is based on results from the phase 3 BALATON and COMINO st
- Sight Sciences' Glaucoma and Dry Eye Technologies to be Featured in Multiple Clinical Presentations at the 2023 ASCRShttps://modernod.com/news/sight-sciences-glaucoma-and-dry-eye-technologies-to-be-featured-in-multiple-clinical-presentations-at-the-2023-ascrs/2481590/Sight Sciences announced that two of its proprietary glaucoma and dry eye technologies, the Omni Surgical System and the TearCare System, will be featured in oral presentations and one poster at this year's ASCRS annual meeting in San Diego. The Omni Surgical System technology
- Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-receives-fda-clearance-of-ind-application-for-atsn-201-an-investigational-gene-therapy-for-the-treatment-of-x-linked-retinoschisis/2481580/Atsena Therapeutics, a clinical-stage gene therapy company, announced the FDA has cleared the company’s investigational new drug (IND) application for a phase 1/2 clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS). ATSN-201 leverages one of the company&rsquo
- Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase 1/2 Clinical Trial of ATSN-101 in Patients with LCA1https://modernod.com/news/atsena-therapeutics-announces-positive-6-month-data-from-ongoing-phase-12-clinical-trial-of-atsn-101-in-patients-with-lca1/2481563/Atsena Therapeutics announced positive 6-month safety and efficacy data from the ongoing phase 1/2 clinical trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). The data were presented by Chris
- eSight Names New Senior Leadershiphttps://modernod.com/news/esight-names-new-senior-leadership/2481562/eSight announced the selection of John Tushar as the new Chairman of the Board; Aaron Tutwiler as the new CEO; and Roland Mattern as Director of Sales and Marketing. In these new roles, the three senior leaders will drive forward the execution of the company’s long-term
- Ciliatech Raises Money to Advance Development of Disruptive Glaucoma Implanthttps://modernod.com/news/ciliatech-raises-money-to-advance-development-of-disruptive-glaucoma-implant/2481560/Ciliatech announced it has raised €3.5M (about $4 million) to advance the company's glaucoma implant, CID (Cilio-scleral Inter-positioning Device), a technology that aims to disrupt traditional approaches in glaucoma surgery. Ciliatech says CID differs from other glau
- Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at ASCRS and ARVOhttps://modernod.com/news/azura-ophthalmics-to-present-new-data-on-azr-md-001-in-meibomian-gland-dysfunction-at-ascrs-and-arvo/2481544/Azura Ophthalmics announced multiple presentations featuring positive efficacy and safety data from a phase 2b study of the company’s lead drug candidate, AZR-MD-001, in Meibomian Gland Dysfunction (MGD). Data will be featured at the upcoming Annual Meetings for the Association for Research
- Visus Therapeutics Announces New Scientific Data to Be Presented at ARVO 2023https://modernod.com/news/visus-therapeutics-announces-new-scientific-data-to-be-presented-at-arvo-2023/2481541/Visus Therapeutics announced it will present new scientific data at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held April 23-27, 2023 in New Orleans. The presentations will highlight new research findings on the company’s alpha-cryst
- Peeq Waiva Multipurpose Eyelid Cleansing Device Now Availablehttps://modernod.com/news/peeq-waiva-multipurpose-eyelid-cleansing-device-now-available/2481525/Peeq Pro has announced the launch of the Peeq Waiva, an at-home cleansing device designed for daily use to gently and effectively clean eyelids and the skin around the eyes. When used consistently as part of a patient's at-home eye cleansing routine, the device is designed